Lin Du1, Andrew J Robles, Jarrod B King, Douglas R Powell, Andrew N Miller, Susan L Mooberry, Robert H Cichewicz. 1. Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, 101 Stephenson Parkway Norman, OK 73019-5251 (USA); Natural Products Discovery Group and Institute for Natural Products Applications and Research Technologies, University of Oklahoma (USA).
Abstract
A fundamental component for success in drug discovery is the ability to assemble and screen compounds that encompass a broad swath of biologically relevant chemical-diversity space. Achieving this goal in a natural-products-based setting requires access to a wide range of biologically diverse specimens. For this reason, we introduced a crowdsourcing program in which citizen scientists furnish soil samples from which new microbial isolates are procured. Illustrating the strength of this approach, we obtained a unique fungal metabolite, maximiscin, from a crowdsourced Alaskan soil sample. Maximiscin, which exhibits a putative combination of polyketide synthase (PKS), non-ribosomal peptide synthetase (NRPS), and shikimate pathway components, was identified as an inhibitor of UACC-62 melanoma cells (LC50=0.93 μM). The metabolite also exhibited efficacy in a xenograft mouse model. These results underscore the value of building cooperative relationships between research teams and citizen scientists to enrich drug discovery efforts.
A fundamental component for success in drug discovery is the ability to assemble and screen compounds that encompass a broad swath of biologically relevant chemical-diversity space. Achieving this goal in a natural-products-based setting requires access to a wide range of biologically diverse specimens. For this reason, we introduced a crowdsourcing program in which citizen scientists furnish soil samples from which new microbial isolates are procured. Illustrating the strength of this approach, we obtained a unique fungal metabolite, maximiscin, from a crowdsourced Alaskan soil sample. n class="Chemical">Maximiscin, which exhibits a putative combination of polyketide synthase (PKS), non-ribosomal peptide synthetase (NRPS), and shikimate pathway components, was identified as an inhibitor of UACC-62 melanoma cells (LC50=0.93 μM). The metabolite also exhibited efficacy in a xenograft mouse model. These results underscore the value of building cooperative relationships between research teams and citizen scientists to enrich drug discovery efforts.
Authors: Raina M Merchant; David A Asch; John C Hershey; Heather M Griffis; Shawndra Hill; Olivia Saynisch; Alison C Leung; Jeremy M Asch; Kirk Lozada; Lindsay D Nadkarni; Austin Kilaru; Charles C Branas; Eric M Stone; Larry Starr; Frances Shofer; Graham Nichol; Lance B Becker Journal: Circ Cardiovasc Qual Outcomes Date: 2013-03-12
Authors: Lin Du; Jarrod B King; Brian H Morrow; Jana K Shen; Andrew N Miller; Robert H Cichewicz Journal: J Nat Prod Date: 2012-10-09 Impact factor: 4.050
Authors: Jin Woo Lee; Jennifer E Collins; Karen L Wendt; Debopam Chakrabarti; Robert H Cichewicz Journal: J Nat Prod Date: 2021-02-10 Impact factor: 4.050
Authors: Andrew J Robles; Shelby McCowen; Shengxin Cai; Michaels Glassman; Francisco Ruiz; Robert H Cichewicz; Stanton F McHardy; Susan L Mooberry Journal: J Med Chem Date: 2017-11-03 Impact factor: 7.446
Authors: Yun-Seo Kil; April L Risinger; Cora L Petersen; Susan L Mooberry; Robert H Cichewicz Journal: J Nat Prod Date: 2020-06-08 Impact factor: 4.050